公开(公告)号：KR1020090119159A

公开(公告)日：2009-11-19

申请号：KR1020080045032

申请日：2008-05-15

Applicant: (주)아모레퍼시픽

Inventor： 신동욱 ,  노민수 ,  이형호 ,  이상민 ,  송민정 ,  김한곤

IPC: A61K31/202 ,  A61P3/04

CPC classification number: A61K31/202 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48

Abstract: PURPOSE: A pharmaceutical composition for suppressing adipocyte differentiation and reducing lipid droplet is provided to prevent or treat obesity or lipoma. CONSTITUTION: A pharmaceutical composition of adipocyte differentiation contains arachidonyl dopamine. The pharmaceutical composition prevents adipose tissue enlargement-related disease. The adipose tissue enlargement-related disease is obesity or lipoma. The differentiation of adipocyte is from mesenchymal stem cell to adipocyte. The mesenchymal stem cell is human bone marrow mesenchymal stem cell. A formulation of oral administration is used in the form of pill, powder, suspension, emulsion, syrup, and granule.

Abstract translation: 目的：提供抑制脂肪细胞分化和降低脂滴的药物组合物，以预防或治疗肥胖或脂肪瘤。 构成：脂肪细胞分化的药物组合物含有花生四烯多巴胺。 该药物组合物防止脂肪组织扩大相关疾病。 脂肪组织增生相关疾病是肥胖或脂肪瘤。 脂肪细胞的分化是从间充质干细胞到脂肪细胞。 间充质干细胞是人骨髓间充质干细胞。 口服给药的制剂以丸剂，粉剂，悬浮液，乳剂，糖浆剂和颗粒剂的形式使用。